Pulmonary Hypertension |
||||||||||||
| CVrg’s extensive coverage of Pulmonary Hypertension, including the sub-indications of pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with hypoxia or lung disease, and pulmonary hypertension associated with left heart disease, provides comprehensive support through the life of your PH assets. | ||||||||||||
 Mallory HardenDisease Area Manager, Pulmonary Hypertension Mallory received her Ph.D. in Virology at Harvard University and her B.S. with honors in Neuroscience from Trinity University. Her research background and history of presenting data at premier science conferences, in addition to experience working at a healthcare crossover investment firm in competitive intelligence and market landscaping, provide an excellent foundation for serving CVrg clients. Martha received her doctorate in Molecular Biology from Princeton University and completed postdoctoral training at Stanford University. She is an experienced analyst with broad scientific and therapeutic expertise and strong analytical capabilities and leads CVrg’s pulmonary hypertension team. |
Pulmonary Hypertension, 2018–2027 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market forecasts. KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in PH from CVrg Sentinel, Conference, Insights and Advisory research are also included. |
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of PH assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why.
CVrg experts conduct primary research with KOLs in PH, using their critical eyes to evaluate emerging trends, pipelines products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today. *Additional fees may apply.
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in PH drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe. |
||||||||||
|
Pricing & Information: Call: 541-977-1516 e-mail: blackwelder@cv-rg.com
|
||||||||||||
